Will This Analyst Upgrade Help NuVasive (NUVA) Stock Today?

NEW YORK (TheStreet) -- Brean Capital upgraded NuVasive  (NUVA)  to "buy" from "hold" and set a $44 price target.

The firm said the stock has pulled back, even though fundamentals have improved.

The stock closed at $35.02 on Monday.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Separately, TheStreet Ratings team rates NUVASIVE INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate NUVASIVE INC (NUVA) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the company's return on equity has been disappointing."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Masimo's Stock Is a Great Buy Right Now

NXPI, AAPL, C: Jim Cramer's Views

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

NuVasive (NUVA) Stock Tumbles on Q3 Revenue Miss, Outlook